FDA approves drug to help prevent spread of HIV infection

Article

For the first time, we have a drug in our arsenal to help prevent the spread of HIV infection to uninfected individuals.

  • Two-drug combination shown effective for pre-exposure prophylaxis

  • Confirmation of HIV-1-negative status necessary prior to prescription to prevent development of resistance

For the first time, we have a drug in our arsenal to help prevent the spread of HIV infection to uninfected individuals.

The United States Food and Drug Administration (FDA) recently approved Truvada (a fixed dose combination of 2 older HIV drugs emtricitabine and tenofovir disoproxil fumarate) (Gilead Sciences, Inc., Foster City, CA) to reduce the risk of HIV infection in uninfected people who are at high risk of contracting the infection through sexual activity with HIV-infected partners. The approval is for pre-exposure prophylaxis (PrEP) only.

FDA previously approved Truvada in 2004 for use in combination with other antiretroviral agents for the treatment of HIV-infected adults and children age 12 years and older.

The current approval is based on results from 2 large trials. The first showed that the drug could reduce risk of HIV transmission by 42% between male partners. The second demonstrated the drug could reduce risk of transmission by up to 75% in opposite-sex pairs.

Both FDA and the drug’s manufacturer, Gilead, emphasize that Truvada taken once daily does not replace safe-sex practices. It is to be used in combination with condoms and regular HIV testing. In fact, to avoid creating HIV-1-resistant variants, physicians can only prescribe the agent to people confirmed to be HIV-negative before beginning treatment who agree to HIV testing every 3 months. A condition of FDA approval is that the manufacturer collect viral isolates from people who acquire HIV while taking the drug so that the isolates can be evaluated for resistance.

No new side effects have been reported with use of Truvada for PrEP; those already known include diarrhea, nausea, abdominal pain, headache, and weight loss. Serious adverse events, although uncommon, include kidney and bone toxicity.

The price tag for the once-daily pill is about $1,200 per month.  

Read other articles in this issue of Special Delivery

Recent Videos
Revi System shows efficacy against urgency urinary incontinence | Image Credit: ics.org.
1 expert is featured in this series.
Researchers highlight risks of breastfeeding while taking Levetiracetam | Image Credit: uwaterloo.ca.
Ipek Ensari, PhD, highlights improved mental health in chronic pelvic pain from physical activity | Image Credit: scholars.mssm.edu
New pSNM system empowers patients in urge urinary incontinence treatment | Image Credit: trinityhealthmichigan.org.
Jannah Thompson, MD, highlights battery free device for UUI management | Image Credit: trinityhealthmichigan.org
Anietie Aliu, PhD, highlights racial barriers to breast cancer screening | Image Credit: bbc.com.
Anietie Aliu, PhD, discusses how to improve breast cancer screening disparities | Image Credit: bbc.com
Jennifer Payne, MD, highlights how to help young women with perimenopause symptoms | Image Credit: uvahealth.com/findadoctor.
Perimenopausal symptoms in young women discussed by Jennifer Payne, MD | Image Credit: uvahealth.com/findadoctor.
Related Content
© 2025 MJH Life Sciences

All rights reserved.